Skip to main content

Table 3 (abstract O3). Mean Absolute Change in ppFEV1 and Sweat Chloride (SwCl)

From: Abstracts from the 23rd Italian congress of Cystic Fibrosis and the 13th National congress of Cystic Fibrosis Italian Society

 

F508del/MF

F508del/F508del a

(all received active TEZ/IVA)

n

ppFEV1

SwCl (mmol/L)

n

ppFEV1

SwCl (mmol/L)

Through day 29b

 VX-440 (600 mg q12h)c + TEZ/IVAd

18

+12.0*

-33.1*

20

+9.5*

-31.3*

 Placebo

11

+1.4

+1.6

6

-2.5

+2.1

Day 15

 VX-152 (200 mg q12h)c + TEZ/IVAe

10

+9.7†

-14.1‡

10

+7.3‡

-20.9†

 Placebo

5

-0.9

+1.0

4

-1.4

+3.4

 VX-659 (120 mg q12h)c + TEZ/IVAe

9

+9.6‡

-41.6*

   

 Placebo

3

-0.4

-11.0

   
  1. a4-wk run-in period on TEZ/IVA. bAverage of days 15 and 29. cMax dose tested. dTEZ (50 mg q12h) + IVA (300 mg q12h). eTEZ (100 mg qd) + IVA (150 mg q12h). *P<0.0001. †P<0.01. ‡P<0.05. VX-440, least squares means; VX-152 and -659, observed means
Back to article page

Italian Journal of Pediatrics

ISSN: 1824-7288

Contact us